Disease · MONDO_0016702

oligoastrocytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. oligoastrocytoma. Diseases, record MONDO_0016702. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016702

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: oligoastrocytoma; Open Targets
Open Targets ID: MONDO_0016702; Open Targets
Other names: MOA, WHO grade II mixed glioma, glioma, mixed, benign, mixed astrocytic-oligodendroglial neoplasm, mixed astrocytic-oligodendroglial tumor, mixed astrocytic-oligodendroglial tumour, mixed astrocytoma-oligodendroglioma, mixed oligo-astrocytoma, mixed oligoastrocytoma, mixed oligodendroglioma-astrocytoma, oligoastroglioma; Open Targets
Disease Ontology: DOID:7912; Disease Ontology
NCI Thesaurus: C4050; NCI Thesaurus
Orphanet: ORPHA:251656; Orphanet
Highest stage of its drugs: Phase 2, for 10 of its 16 drugs, from ClinicalTrials.gov; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CHLOROTOXIN	CHEMBL4298122		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PALBOCICLIB	CHEMBL189963	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROCARBAZINE HYDROCHLORIDE	CHEMBL1200410	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE SULFATE	CHEMBL501867	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets26

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
CCND1	CDK6/cyclin D1	1	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/595	Drugs and targets
CDK4	Cyclin-dependent kinase 4/cyclin D1	1	Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets
CDK6	CDK6/cyclin D1	1	CDK6/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/1021	Drugs and targets
CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1438	Drugs and targets
CSF2RB	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1439	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 26

See all 26 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00049127	Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor	Phase 1/2	64	2014-10-06	Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT02530320	Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved	Phase 2	34	2024-11-22	Oligodendroglioma, Oligoastrocytoma	PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT00039364	Imatinib Mesylate in Treating Patients With Gliomas	Phase 2	112		Brain and Central Nervous System Tumors	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT00002806	Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma	Phase 2	43		Brain and Central Nervous System Tumors	LOMUSTINE, PROCARBAZINE HYDROCHLORIDE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00008008	Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma	Phase 2	40		Brain and Central Nervous System Tumors	FILGRASTIM, SARGRAMOSTIM, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT00303849	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Phase 1/2	33		Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma	CARBOPLATIN, ETOPOSIDE PHOSPHATE, MANNITOL, MELPHALAN, SODIUM THIOSULFATE	Its record names the disease	ClinicalTrials.gov
NCT00400816	Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma	Phase 2	29		Central Nervous System Tumors, Brain Tumor	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02549833	Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma	Phase 1	28		Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, Glioma, Malignant Glioma, Oligoastrocytoma, Mixed	HILTONOL	Its record names the disease	ClinicalTrials.gov
NCT00795457	Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas	Early phase 1	13		Astrocytoma, Oligo-Astrocytoma, Glioma	HILTONOL	Its record names the disease	ClinicalTrials.gov
NCT00362570	Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma	Phase 2	1		Oligoastrocytoma, Mixed, Anaplastic Oligodendroglioma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18824712	RESULT	1	PubMed
12525516	RESULT	1	PubMed
34882581	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016702

GET https://conductscience.org/api/diseases/v1/MONDO_0016702/targets?page=2

API reference For AI assistants